Singapore Exchange (SGX) announced that it has welcomed Hyphens Pharma International Limited to its Catalist under the stock code “1J5”.
Hyphens Pharma International Limited is one of Singapore’s leading specialty pharmaceutical and consumer healthcare groups with a diverse footprint in ASEAN countries.
The Group is in the business of selling and marketing of specialty pharmaceutical products for brand principals mainly from Europe and the United States; developing, marketing and selling its own proprietary range of dermatological products and health supplement products through Hyphens and Ocean Health Singapore; and wholesaling pharmaceuticals and medical supplies in Singapore through Pan-Malayan, a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.
Lim See Wah, Chairman, Executive Director and CEO, Hyphens Pharma International Limited, said:
We are encouraged by the strong response for our IPO, which is a clear signal of investors’ confidence in the Group’s strong track record and network, our portfolio of internationally well-known specialty pharmaceutical products as well as proprietary range of products and brands. With the success of our IPO, we are well-placed to expand and strengthen our product range and maintain growth momentum through scaling our presence in markets that we operate in and expanding into new geographical markets. We are delighted to have our stakeholders participate alongside our growth story.
Mohamed Nasser Ismail, Head of Equity Capital Market (SME) and Head of Capital Market Development at SGX, added:
We are delighted to welcome Hyphens Pharma International Limited to Catalist, an established player in the specialty pharmaceutical and consumer healthcare space in Singapore, with a brand heritage of more than 70 years. This is a timely listing as the Group looks set to deepen its presence in existing markets and further internationalise its business, at a time when demand for high quality wellness products continues to increase. Through this listing, investors will also have an opportunity to partake in the growing healthcare industry.
With a market capitalisation of S$78 million, the listing of Hyphens Pharma International Limited brings the total number of healthcare companies listed on SGX to 38, with a combined market capitalisation of more than S$63 billion. The total number of companies listed on Catalist rises to 205, with a combined market capitalisation of over S$12 billion.
Hyphens Pharma International Limited opened at S$0.30 today.